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Abstract: Cardiac allograft vasculopathy (CAV) is an entity unique to the cardiac transplant patients and remains the 
leading cause of mortality after the first year of transplantation causing chronic allograft rejection. It is an accelerated 
form of coronary artery disease, occurring diffusely, starting from the small distal vessels and ultimately extending to 
intramyocardial and epicardial vessels of the allograft. Multiple traditional metabolic risk factors known to cause 
atherosclerosis have been identified as a trigger for CAV. Moreover, several nontraditional environmental risk factors 
such as viral infections, donor’s age, underlying cardiac disease and mechanism of donor brain death have also been 
implicated. The pathogenesis of CAV is complex with involvement of both immunological and non-immunological 
mechanisms and still remains poorly understood. Clinical diagnosis of CAV is difficult as symptoms of angina are usually 
lacking because of denervated nature of the allograft and it is identified when the graft is already compromised. 
Currently, invasive testing stands as the gold standard for its diagnosis; however its utility has been questioned. 
Coronary CT angiography (CCTA) has emerged as a promising noninvasive tool for the diagnosis of CAV. This review 
discusses the risk factors, pathogenesis and diagnosis of CAV and utility of CCTA in its diagnosis and surveillance. 
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INTRODUCTION 
Cardiac transplantation has emerged as an effective 
treatment modality for patients with end stage heart 
failure. Over 5,000 heart transplants are performed 
every year worldwide [1], and about 50% of those are 
performed in the United States alone [2]. Significant 
advances in cardiac transplantation and post transplant 
care over the last three decades have led to substantial 
improvement in the overall survival of cardiac 
transplant patients. As the long-term survival of 
transplant recipients continues to increase, cardiac 
allograft vasculopathy (CAV) has emerged as an 
important cause of morbidity and mortality after the first 
year of heart transplantation. CAV may begin during 
the first twelve months after cardiac transplantation and 
has been reported as an independent predictor of 
mortality [3]. Despite the fact that CAV is one of the 
leading causes of late graft failure; its exact 
pathogenesis remains unclear. Many believe that CAV 
is the result of a chronic allograft rejection; however 
increasing evidence shows involvement of both 
immunological and non-immunological mechanisms [4]. 
In the current era, coronary angiography is the gold 
standard method for its diagnosis. Increasing efforts 
are being made to study non-invasive imaging 
techniques for its diagnosis. Coronary computed  
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tomography angiography (CCTA) has emerged as a 
noninvasive tool to assess coronary artery disease in 
symptomatic patients with low to intermediate pretest 
probability of obstructive CAD and there is growing 
evidence that CCTA might be a valuable tool in the 
early detection of CAV.  
This review focuses on pathogenesis of CAV and 
the usefulness of CCTA in the diagnosis and 
surveillance of CAV.  
WHAT IS CAV?  
Cardiac Allograft Vasculopathy is an entity unique to 
cardiac transplant patients and remains the leading 
cause of mortality after the first year of transplantation 
causing chronic allograft rejection. It has been referred 
to as the Achilles heel of cardiac transplantation by 
many authors [5]. It is a rapidly progressive form of 
diffuse coronary artery disease (CAD) starting from the 
small distal vessels and ultimately extending to 
intramyocardial and epicardial vessels of the allograft 
[6]. It is characterized by predominantly concentric 
intimal proliferation sparing the internal elastic lamina, 
causing luminal narrowing, occlusion of smaller arteries 
and ischemic graft failure [7, 8]. This is in contrast to 
traditional native coronary artery atherosclerosis that is 
a relatively focal process and is usually characterized 
by eccentric intimal proliferation and disruption of the 
internal elastic lamina. CAV affects about 8% of the 
transplant recipients by one year, 30% by five years, 
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and 50% by ten years after transplantation [1, 9]. It has 
a high mortality rate (about 90%) in the first year of 
diagnosis in patients with 3-vessel CAV [10] and the 
only definitive treatment is re-transplantation, which by 
itself has a poor prognosis. Therefore, research efforts 
should focus on the early detection and targeted 
treatment interventions of CAV. 
RISK FACTORS 
Multiple traditional metabolic risk factors known to 
cause atherosclerosis can trigger development of CAV 
[11]. These include pre-existing hyperlipidemia, 
hypertension, and diabetes. Sanchez et al. [11] showed 
that dyslipidemia of the recipient is strongly associated 
with development of CAV and that the other metabolic 
risk factors such as age, sex, body mass index, 
diabetes mellitus, hypertension and smoking are only 
weakly associated.  
Environmental risk factors have also been linked to 
the development of CAV. Of these, viral infections have 
been studied extensively with cytomegalovirus being 
the best-described [12]. Risk factors such as the 
donor’s and recipient’s age and sex, underlying cardiac 
disease, doses of immunosuppressive agents, HLA 
mismatch [13, 14], also play an important role in the 
development of CAV [13, 15]. Mehra et al. showed that 
explosive brain death of the donor is a significant 
determinant of late development of CAV in transplant 
recipients and also affects long-term survival of the 
allograft [16].  
PATHOGENESIS 
The pathogenesis of CAV is complex and remains 
poorly understood. Both immunological and non-
immunological mechanisms have been found to play a 
role in its pathogenesis [17].  
Immunological 
CAV has long been understood as a process of 
chronic rejection with an overwhelming role of 
alloimmunity in its pathogenesis. The observation that 
CAV affects the donor arteries and not the recipient 
arteries supports alloimmunity as the main process in 
CAV. The alloantigen-dependent risk factors include 
HLA mismatches and the number and duration of acute 
rejection episodes [13, 14]. HLA matching has been 
found to be an independent predictor of survival in 
heart transplantation [18]. Both innate and acquired 
components of the immune system have been 
implicated in the pathogenesis of CAV [19]. The first 
target of the immunological activation is the 
endothelium and the inflammation caused by the 
release of various cytokines and chemokines results in 
migration and proliferation of smooth muscle cells 
causing intimal thickening and fibroblast activation 
triggering fibrosis [20].  
Non-Immunological  
Several non-immunological factors have been 
implicated in the development of CAV after cardiac 
transplantation.  
a) Cytomegalovirus Infection 
CAV occurs more frequently in patients who 
develop cytomegalovirus (CMV) infection with or 
without symptoms after transplant [21]. These patients 
typically have a more severe form of CAV compared to 
patients without CMV infection [21]. The risk of 
developing CMV infection varies with the 
immunosuppressive agent being used. For example, 
higher incidence of CMV infection was found with 
mycophenolate mofetil compared to azathioprine [22] 
while the incidence remained similar with use of 
cyclosporine and tacrolimus [23, 24]. Prophylactic use 
of ganciclovir has been shown to reduce intimal 
thickening, decrease progression of CAD and offer a 
survival benefit [25]. Ganciclovir in combination with 
hyper-immune CMV globulin has proven to be more 
effective than ganciclovir alone [26]. 
b) Metabolic Factors 
The prevalence of conventional cardiovascular risk 
factors such as diabetes, hypertension and 
hyperlipidemia is likely to be higher in the cardiac 
transplant patients compared to the general population. 
The use of corticosteroids and immunosuppressive 
chemotherapeutic regimens also contributes to the 
development of diabetes and hypertension after 
transplant. New onset diabetes occurs in about one-
third of patients post transplant [27], while hypertension 
requiring treatment occurs in majority of patients within 
six months of cardiac transplant [28].  
c) Ischemia-Reperfusion Injury 
Ischemia disrupts the blood supply causing 
anaerobic cell metabolism, depletion of energy 
molecules and dysfunction of ATP dependent 
membrane channels. As reperfusion occurs, highly 
reactive oxygen free radicals are generated which 
cause activation of endothelial cells [29]. These 
activated cells produce mediators such as platelet-
activating factor (PAF), and surface adhesion 
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molecules. These lead to attachment of circulating 
leukocytes with the endothelial cells resulting in direct 
endothelial cell damage. These leukocytes further 
release cytokines that results in proliferation of smooth 
muscle cells and contributes to development of graft 
vasculopathy [30].  
d) Other Donor and Recipient Related Factors 
Graft injury can occur in cases of brain death, donor 
maintenance and organ retrieval and preservation 
process [31]. Pre-existing CAD even in young donors is 
frequent. However, donor transmitted lesions have not 
been reported to cause accelerated graft vasculopathy 
in current studies [32]. 
CLINICAL PRESENTATION  
The diagnosis of CAV is clinically difficult as 
symptoms of angina are mostly absent because of the 
denervated nature of the allograft. Thus, it is usually 
identified late when the graft is already compromised. 
The typical presentation of CAV includes shortness of 
breath, decrease in exercise capacity, syncope, heart 
failure, ventricular arrhythmias or sudden cardiac death 
which could be the initial presentation of the disease 
[33]. Studies have shown that timely alterations in the 
immunosuppressive regimen can delay the 
development and progression of CAV and even cause 
its regression [34]. With the advent of newer 
immunosuppressive agents, early diagnosis has 
become imperative as it can facilitate the essential 
modifications in the medication regimen before 
reaching a stage where revascularization or 
retransplantation will be the only alternative.  
DIAGNOSTIC TESTING 
In the past, CAV was diagnosed with 
histopathological examination only. Currently, coronary 
angiography stands as the gold standard for the 
evaluation of CAV and is the norm for surveillance in 
cardiac transplant patients. However, coronary 
angiography lacks sensitivity in identifying the extent 
and severity of CAV when compared with 
histopathologic examination [35] and intravascular 
ultrasonography [36]. The associated risks that 
invasive procedures carry and the risk of contrast-
induced nephropathy have led to the advent of 
research for non-invasive imaging modalities that could 
identify CAV in its primitive stages. 
Several noninvasive test modalities including the 
treadmill exercise test, dobutamine stress 
echocardiography, and myocardial perfusion scans 
have also been studied for early diagnosis however 
their modest diagnostic accuracy is the major limitation 
[37, 38]. Coronary CT angiography (CCTA) is an 
upcoming noninvasive modality in detection of CAV.  
Invasive Testing 
Coronary angiography is currently considered the 
gold standard for the evaluation and surveillance of 
CAV [39]. It is universally available for both the adult 
and pediatric population and it is applicable at any time 
after a cardiac transplantation. An angiogram may be 
considered within a month after cardiac transplant to 
establish a baseline of the coronary anatomy. 
Abnormal findings at that time suggest native coronary 
artery disease of the donor and not CAV. Thereafter; 
patients should undergo coronary angiography a year 
after the cardiac transplant. Surveillance is 
recommended every other year in patients without CAV 
and on a yearly basis in those with disease [40]. Some 
transplant centers alternate coronary angiography with 
non-invasive tests such as such as dobutamine stress 
echocardiography or myocardial perfusion imaging to 
limit the radiation exposure [39]. 
Despite its advantages, coronary angiography is an 
invasive test and as such carries its associated risks. It 
has also been shown to underestimate the presence of 
disease compared to histopathologic studies or 
intracoronary ultrasound [41]. In the transplant patients, 
stenosis may develop in a concentric fashion and 
mimic the normal coronary arteries. In other cases 
severe intimal thickening may be compensated by 
remodeling and enlargement of the vessel and thus 
missed by angiography, which provides direct 
visualization of the vessel lumen only.  
Apart from its diagnostic purposes, coronary 
angiography provides significant prognostic 
information: In a study by Yacoub et al. absence of 
angiographic disease was a significant predictor of 
cardiac event-free survival in heart transplant patients 
[42, 43].  
Intravascular Ultrasound (IVUS)  
Intravascular ultrasound (IVUS) has been used for 
imaging of the coronary anatomy in post-transplant 
patients. IVUS allows measurements of both the actual 
lumen diameter and the thickness of the intima and 
media and thus provides invaluable information about 
the onset, severity and progression of CAV [36]. IVUS 
has high sensitivity and negative predictive value 
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however its routine use as a screening tool for CAV is 
not recommended based on the latest guidelines [39, 
42]. The rate of progression and severity of CAV 
assessed by IVUS has been shown to have prognostic 
implications for the risk of heart failure, myocardial 
infarction, death and re-transplantation, however the 
detailed information provided by IVUS does not trigger 
changes in the clinical practice that would change 
those outcomes. Furthermore, its use is costly, 
invasive, time consuming, riskier and allows the 
assessment of proximal epicardial arteries only [41].  
Diagnostic Cardiac Catheterization and Fractional 
Flow Reserve 
Coronary flow reserve (CFR) measures the 
increase in coronary blood flow in response to a 
vasodilator agent. The reduction of CFR indicates the 
development of CAV and helps in detection of the 
disease before angiographic changes occur. Currently 
CFR is the standard for the early detection of CAV 
however it is an invasive procedure and does not allow 
the study of side branches or distal segments of the 
vessels. 
Non-Invasive Testing 
Stress Testing 
In patients with a normal angiogram that are 
considered low-risk for the development of CAV non-
invasive testing can be used to minimize the 
surveillance angiographies [39]. Exercise ECG, 
thallium scintigraphy and exercise radionuclide 
ventriculography are also used in patients with 
advanced renal failure to reduce the administration of 
contrast. These tests have low sensitivities but good 
negative predictive value: Patients with a normal stress 
test have been shown to be free of adverse events. 
Dobutamine echocardiography has been shown to 
have better sensitivities and specificities compared with 
the other non-invasive tests [37]. Lewis et al. evaluated 
patients on a yearly basis with dobutamine 
echocardiography. Their data suggested an abnormal 
test serves as an important predictor of subsequent 
cardiac events while a normal test identified a subset of 
low risk patients [37, 44].  
Coronary CT Angiography  
Cardiac CT angiography (CCTA) has arisen as a 
non-invasive test for the assessment of the coronary 
anatomy allowing visualization of the wall of the 
coronary arteries and thus potentially detecting CAV in 
earlier stages compared to coronary angiography [45, 
46]. In a recent study published in the New England 
Journal of Medicine, CCTA was able to accurately 
identify the presence and the severity of obstructive 
coronary artery disease [47]. However, the negative 
and positive predictive value of 83% and 91% 
respectively of the CCTA reveal that coronary 
angiography cannot be replaced as the gold standard 
for the assessment of post-transplant patients [47].  
Limitations of the CCTA include the high radiation 
exposure, with an average radiation dose of 10-20mSv 
(when performed with retrospective gating) [48] 
compared to 5-6mSv [49] that is the average radiation 
dose of invasive angiography, and the concerns that 
increased doses of radiation could translate into higher 
risk of cancer in this patient population that is of high 
risk given the prolonged use of immunosuppressant 
medications [42, 50, 51]. The risk of contrast-induced 
nephropathy (CIN) is also noteworthy: Higher doses of 
contrast are used in CCTA compared to conventional 
coronary angiography with the majority of the post-
transplant patients having a degree of renal dysfunction 
at baseline. The denervated hearts lack vagal tone and 
usually do not respond well to the beta-blockers given 
to slow the heart rate for obtaining optimal CCTA 
images. Furthermore the use of beta-blockers in these 
patients has raised safety concerns with regards to 
their use in this patient population [50]. Based on the 
current evidence, the routine use of CCTA for the 
assessment of CAV is not recommended as there is 
currently limited evidence on its diagnostic accuracy 
and prognostic value in the post-transplant survival 
[52].  
Magnetic Resonance Imaging (MRI) 
Magnetic resonance perfusion imaging (MRI) using 
gadolinium based contrast has the advantage of being 
a non-invasive test without exposing patients to 
radiation. Currently MRI does not have the resolution to 
accurately define the coronary anatomy the way CCTA 
or coronary angiography do; however; it has been vali-
dated as a tool to quantify myocardial perfusion reserve 
(MPR) in patients with a diagnosis of CAV. Studies 
have shown that MPR matches the reduced coronary 
flow reserve as assessed by angiography [42].  
Biomarkers 
Because inflammation causes endothelial injury, 
measurement of inflammatory cytokines in the serum 
could theoretically help in the detection of CAV.  
Elevated C-reactive peptide (CRP) and brain 
natriuretic peptide (BNP) levels have been associated 
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with increased risk of developing CAV and increased 
mortality [53, 54]. Persistent elevation of troponin-I after 
cardiac transplant was also associated with an 
increased risk of CAV and graft failure. Other cytokines 
associated with endothelial injury such as ICAM-1, 
VCAM-1, endothelin, vascular endothelial growth factor 
(VEGF) and even von-Willebrand factor are currently 
being studied as potential biomarkers and therapeutic 
targets for CAV [42, 55].  
Based on the guidelines, measurement of 
biomarkers is not currently recommended for detection 
or evaluation of the severity of CAV given the lack of 
concrete evidence about their specificity and 
reproducibility [39].  
MANAGEMENT OF CAV 
Once diagnosed, treatment options for CAV are 
somewhat limited and have only minimal impact. 
Therefore, management of CAV focuses on early 
surveillance and primary prevention with optimal 
immunosuppression and aggressive control of 
cardiovascular risk factors.  
Conventionally, immunosuppressive agents of the 
calcineurin inhibitor class have been the cornerstone in 
reducing rejection. mTOR inhibitors such as sirolimus 
and everolimus have antiproliferative actions and have 
been shown to decrease incidence and progression of 
CAV [34, 56]. The use of antiplatelet agents is not well 
studied in this population, however aspirin is empirically 
used for possible microthrombi, which can form at the 
sites of endothelial injury in the coronaries in CAV. 
Statins are part of standard care for post-transplant 
patients: they help not only in lowering cholesterol, but 
have been found useful in the transplant patients given 
their immunosuppressive and anti-inflammatory 
properties [57].  
Revascularization interventions are limited due to 
diffuse nature of the disease in CAV. Percutaneous 
revascularization can be considered for focal disease 
however has not been shown to be beneficial 
compared to medical therapy alone. Retransplantation 
has been considered as a treatment option for patients 
with advanced CAV. One recent study showed survival 
benefit when retransplantation was performed in 
patients with CAV for associated systolic graft 
dysfunction compared to medical therapy alone [58]. 
However, retransplantation is associated with the 
challenges of organ shortage and the increased risk of 
CAV compared to first transplantation. Thus, current 
consensus recommendation is that it should be 
reserved only for selected patients with advanced CAV 
[59].  
CONCLUSION  
CAV is a major cause of death in heart transplant 
patients. Invasive testing remains the gold standard in 
its diagnosis, however the emerging noninvasive 
modalities hold great potential in reliable detection of 
CAV and reducing the need for invasive testing. 
Surveillance measures and primary prevention 
strategies are crucial as the treatment of CAV is 
limited.  
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